The organizational redesign, initiated in April 2024, is on track with the aim to streamline structures and reduce operating costs across most areas of the company. Rightsizing the company with a focus on trimming residual pandemic infrastructure is ongoing, with a planned reduction of 150 positions by year end. The organizational redesign is tailored to CureVac’s business scope and pipeline priorities, significantly increasing efficiency and performance while maintaining a strong focus on innovation and R&D activities. The redesign will continue throughout 2024 through measures that are expected to result in financial savings from the second half of 2024 onwards and extend the company’s cash runway into the fourth quarter of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVAC:
- CureVac price target lowered to $14 from $18 at UBS
- Curevac’s Market Forecast Risks: Miscalculations and Trial Participant Challenges Threaten Profitability
- CureVac downgraded to Market Perform from Outperform at Leerink
- CureVac N.V. Reports Strong 2023 Finances and Strategic Advances
- CureVac Launches Study for H5N1 Influenza Vaccine